Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Pemetrexed

FDA-approved product (solution, intravenous), marketed as Pemetrexed, Pemfexy, Axtle and 3 more.

Registered studies
50+
Lab records
6
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Pemetrexed
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Adenocarcinoma
  • Cancer
  • Large cell lung carcinoma
  • Lung large cell carcinoma
  • Malignant Mesothelioma
  • Malignant peritoneal mesothelioma
  • Malignant pleural mesothelioma
  • Mesothelioma
  • Neoplasm
  • Non-small cell lung carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Folic acid analogues
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA35.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli13.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae28.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis48.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • E. coli: measured active in 2 of 6 lab records
Open Pemetrexed in ChEMBL Registered studies below
Show the 6 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Pemetrexed with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • JSKN033 Versus Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer

    NCT07797153 · start 2026-09

    Registered record
    Registry ID
    NCT07797153
    Conditions
    Recurrent or Metastatic Cervical Cancer
    Interventions
    JSKN033; Docetaxel; Topotecan; Gemcitabine (GEM); Pemetrexed
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-09
    Completion
    2029-12
    Enrolment
    368

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent or Metastatic Cervical Cancer
    InterventionJSKN033; Docetaxel; Topotecan; Gemcitabine (GEM) +1 more
    PhasePhase 3
    Registry statusNot yet recruiting

  • A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

    NCT07680764 · start 2026-08-31

    Registered record
    Registry ID
    NCT07680764
    Conditions
    Locally Advanced Non-Small Cell Lung Cancer (NSCLC); Metastatic Non-Small Cell Lung Cancer (NSCLC)
    Interventions
    Pumitamig; Imzokitug; Pemetrexed; Cisplatin; Carboplatin; Paclitaxel; Infliximab; Vedolizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-08-31
    Completion
    2030-09-15
    Enrolment
    160

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLocally Advanced Non-Small Cell Lung Cancer (NSCLC); Metastatic Non-Small Cell Lung Cancer (NSCLC)
    InterventionPumitamig; Imzokitug; Pemetrexed; Cisplatin +4 more
    PhasePhase 2
    Registry statusRecruiting

  • A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

    NCT07415031 · start 2026-05-06

    Registered record
    Registry ID
    NCT07415031
    Conditions
    Solid Tumors
    Interventions
    Adagrasib; Pembrolizumab; Cetuximab; Pemetrexed; Docetaxel; Irinotecan; Leucovorin; Oxaliplatin; Fluorouracil
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-05-06
    Completion
    2028-02-16
    Enrolment
    170

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumors
    InterventionAdagrasib; Pembrolizumab; Cetuximab; Pemetrexed +5 more
    PhasePhase 2
    Registry statusRecruiting

  • A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung Cancer

    NCT07381829 · start 2025-10-27

    Registered record
    Registry ID
    NCT07381829
    Conditions
    Advanced Solid Tumor Cancer
    Interventions
    HC010; Paclitaxel (Chemotherapy); Pemetrexed; Etoposide; Carboplatin/Cisplatin; Docetaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2025-10-27
    Completion
    2026-12-30
    Enrolment
    328

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Solid Tumor Cancer
    InterventionHC010; Paclitaxel (Chemotherapy); Pemetrexed; Etoposide +2 more
    PhasePhase 1
    Registry statusRecruiting

  • Iparomlimab and Tuvonralimab Plus Chemotherapy for Inducing Conversion to Resectability in Initially Unresectable Stage III NSCLC

    NCT07139041 · start 2025-10

    Registered record
    Registry ID
    NCT07139041
    Conditions
    NSCLC (Non-small-cell Lung Cancer)
    Interventions
    Iparomlimab and tuvonralimab plus chemotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2025-10
    Completion
    2029-06
    Enrolment
    69

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNSCLC (Non-small-cell Lung Cancer)
    InterventionIparomlimab and tuvonralimab plus chemotherapy
    PhasePhase 2
    Registry statusNot yet recruiting

  • A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)

    NCT06946797 · start 2025-09-19

    Registered record
    Registry ID
    NCT06946797
    Conditions
    Non-Small Cell Lung Cancer
    Interventions
    Nivolumab; Ipilimumab; Carboplatin; Paclitaxel; Pemetrexed; Cisplatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2025-09-19
    Completion
    2028-10-25
    Enrolment
    76

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer
    InterventionNivolumab; Ipilimumab; Carboplatin; Paclitaxel +2 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer

    NCT06865339 · start 2025-08-07

    Registered record
    Registry ID
    NCT06865339
    Conditions
    NSCLC; Locally Advanced
    Interventions
    Cemiplimab; Fianlimab; Radiotherapy; Platinum Doublet Chemotherapy (PDC)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-08-07
    Completion
    2027-08
    Enrolment
    76

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNSCLC; Locally Advanced
    InterventionCemiplimab; Fianlimab; Radiotherapy; Platinum Doublet Chemotherapy (PDC)
    PhasePhase 2
    Registry statusRecruiting

  • Low Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLC

    NCT07050043 · start 2025-05-19

    Registered record
    Registry ID
    NCT07050043
    Conditions
    NSCLC (Non-small Cell Lung Carcinoma); First Line Therapy; Locally Advanced/Metastatic NSCLC
    Interventions
    Nivolumab 40mg; Cisplatin, Carboplatin, Pemetrexed, Gemcitabine, Paclitaxel, Docetaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-05-19
    Completion
    2030-12-31
    Enrolment
    123

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNSCLC (Non-small Cell Lung Carcinoma); First Line Therapy; Locally Advanced/Metastatic NSCLC
    InterventionNivolumab 40mg; Cisplatin, Carboplatin, Pemetrexed, Gemcitabine, Paclitaxel, Docetaxel
    PhasePhase 3
    Registry statusRecruiting

  • SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC

    NCT07131319 · start 2025-04-21

    Registered record
    Registry ID
    NCT07131319
    Conditions
    Non-Small Cell Lung Cancer
    Interventions
    Spatially Fractionated Radiotherapy (SFRT); Tislelizumab, Carboplatin, Pemetrexed; Tislelizumab, paclitaxel, Carboplatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Recruiting
    Start
    2025-04-21
    Completion
    2028-12-31
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer
    InterventionSpatially Fractionated Radiotherapy (SFRT); Tislelizumab, Carboplatin, Pemetrexed; Tislelizumab, paclitaxel, Carboplatin
    PhasePhase 2 / Phase 3
    Registry statusRecruiting

  • Intrathecal PD-1/VEGF Bispecific Antibody Plus Pemetrexed for Leptomeningeal Metastasis

    NCT06809517 · start 2025-03-18

    Registered record
    Registry ID
    NCT06809517
    Conditions
    Leptomeningeal Metastasis; Intrathecal Drug Delivery
    Interventions
    AK112; Pemetrexed (Alimta)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2025-03-18
    Completion
    2026-05-01
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeptomeningeal Metastasis; Intrathecal Drug Delivery
    InterventionAK112; Pemetrexed (Alimta)
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC

    NCT06883630 · start 2025-03-13

    Registered record
    Registry ID
    NCT06883630
    Conditions
    Non-Small Cell Lung Cancer
    Interventions
    RC148 plus Carboplatin and Paclitaxel/pemetrexed; RC148
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2025-03-13
    Completion
    2027-07-31
    Enrolment
    121

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer
    InterventionRC148 plus Carboplatin and Paclitaxel/pemetrexed; RC148
    PhasePhase 1
    Registry statusActive not recruiting

  • A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

    NCT06607185 · start 2024-10-21

    Registered record
    Registry ID
    NCT06607185
    Conditions
    Pancreatic Ductal Adenocarcinoma; Non-small Cell Lung Cancer; Colorectal Cancer; Advanced Solid Tumor; Metastatic Solid Tumor
    Interventions
    LY4066434.; Cetuximab; Nab paclitaxel; Gemcitabine; Oxaliplatin; Leucovorin; Irinotecan; 5Fluorouracil; Carboplatin; Cisplatin; Pemetrexed; Pembrolizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2024-10-21
    Completion
    2030-01
    Enrolment
    750

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPancreatic Ductal Adenocarcinoma; Non-small Cell Lung Cancer; Colorectal Cancer; Advanced Solid Tumor +1 more
    InterventionLY4066434.; Cetuximab; Nab paclitaxel; Gemcitabine +8 more
    PhasePhase 1
    Registry statusActive not recruiting

  • A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

    NCT06452277 · start 2024-08-28

    Registered record
    Registry ID
    NCT06452277
    Conditions
    Advanced Non-small Cell Lung Cancer, HER2 Mutation
    Interventions
    Sevabertinib; Pembrolizumab; Cisplatin; Carboplatin; Pemetrexed
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2024-08-28
    Completion
    2029-06-27
    Enrolment
    444

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Non-small Cell Lung Cancer, HER2 Mutation
    InterventionSevabertinib; Pembrolizumab; Cisplatin; Carboplatin +1 more
    PhasePhase 3
    Registry statusRecruiting

  • A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer

    NCT06348199 · start 2024-03-12

    Registered record
    Registry ID
    NCT06348199
    Conditions
    Non-small Cell Lung Cancer Stage IV
    Interventions
    SB27; Keytruda
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2024-03-12
    Completion
    2026-09
    Enrolment
    555

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-small Cell Lung Cancer Stage IV
    InterventionSB27; Keytruda
    PhasePhase 3
    Registry statusActive not recruiting

  • Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Stage Ⅲ Unresectable Non-small Cell Lung Cancer

    NCT06357598 · start 2024-01-18

    Registered record
    Registry ID
    NCT06357598
    Conditions
    Non-small-cell Lung Cancer (NSCLC)
    Interventions
    Tislelizumab; Pemetrexed (Non-squamous NSCLC) or Nab-paclitaxel(Squamous NSCLC); Carboplatin or Cisplatin; Surgery
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2024-01-18
    Completion
    2025-12-31
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-small-cell Lung Cancer (NSCLC)
    InterventionTislelizumab; Pemetrexed (Non-squamous NSCLC) or Nab-paclitaxel(Squamous NSCLC); Carboplatin or Cisplatin; Surgery
    PhasePhase 4
    Registry statusUnknown